Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Assets: 2010-2025

Historic Assets for Arrowhead Pharmaceuticals (ARWR) over the last 15 years, with Sep 2025 value amounting to $1.4 billion.

  • Arrowhead Pharmaceuticals' Assets rose 21.54% to $1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year increase of 21.54%. This contributed to the annual value of $1.4 billion for FY2025, which is 21.54% up from last year.
  • Per Arrowhead Pharmaceuticals' latest filing, its Assets stood at $1.4 billion for Q3 2025, which was up 0.34% from $1.4 billion recorded in Q2 2025.
  • In the past 5 years, Arrowhead Pharmaceuticals' Assets registered a high of $1.6 billion during Q1 2025, and its lowest value of $626.3 million during Q4 2023.
  • Its 3-year average for Assets is $1.0 billion, with a median of $955.1 million in 2024.
  • In the last 5 years, Arrowhead Pharmaceuticals' Assets fell by 29.75% in 2023 and then surged by 64.74% in 2025.
  • Quarterly analysis of 5 years shows Arrowhead Pharmaceuticals' Assets stood at $638.5 million in 2021, then skyrocketed by 39.61% to $891.5 million in 2022, then dropped by 29.75% to $626.3 million in 2023, then skyrocketed by 61.86% to $1.0 billion in 2024, then grew by 21.54% to $1.4 billion in 2025.
  • Its last three reported values are $1.4 billion in Q3 2025, $1.4 billion for Q2 2025, and $1.6 billion during Q1 2025.